Serina Therapeutics, Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Serina Therapeutics, Inc. (SER) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 12.50 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-13
- Serina Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-06-30 was 12.50M shares, a 99.16% increase year-over-year.
- Serina Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 17.43M shares, a 228.76% increase year-over-year.
- Serina Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-09-30 was 7.15M shares, a 76.05% increase year-over-year.
- Serina Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-06-30 was 6.28M shares, a 61.84% increase year-over-year.
- Serina Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 7.15M shares, a 37.06% increase from fiscal 2024.
- Serina Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 5.22M shares, a 1000.84% increase from fiscal 2023.
- Serina Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 474.00K shares.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|
| 2026-06-30 | 12.50M shares 10-Q · filed 2026-08-13 | 12.50M shares 10-Q · filed 2026-08-13 | ||
| 2026-03-31 | 17.43M shares 10-Q · filed 2026-05-14 | |||
| 2025-12-31 | 7.15M shares 10-K · filed 2026-03-25 | |||
| 2025-09-30 | 7.15M shares 10-Q · filed 2025-11-13 | 7.15M shares 10-Q · filed 2025-11-13 | ||
| 2025-06-30 | 6.28M shares 10-Q · filed 2026-08-13 | 6.28M shares 10-Q · filed 2026-08-13 | ||
| 2025-03-31 | 5.30M shares 10-Q · filed 2026-05-14 | |||
| 2024-12-31 | 5.22M shares 10-K · filed 2026-03-25 | |||
| 2024-09-30 | 4.06M shares 10-Q · filed 2025-11-13 | 6.44M shares 10-Q · filed 2025-11-13 | ||
| 2024-06-30 | 3.88M shares 10-Q · filed 2025-08-11 | 5.53M shares 10-Q · filed 2025-08-11 | ||
| 2024-03-31 | 3.84M shares 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | 474.00K shares 10-K · filed 2025-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| TALPHERA, INC. (TLPH) | United States | $0.060B |